• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    GC & Corporate Secretary Smyser Collin covered exercise/tax liability with 10,713 shares and converted options into 11,196 shares, increasing direct ownership by 0.62% to 79,002 units (SEC Form 4)

    5/21/25 4:17:53 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care
    Get the next $OPCH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Smyser Collin

    (Last) (First) (Middle)
    C/O OPTION CARE HEALTH, INC.
    3000 LAKESIDE DRIVE, SUITE 300N

    (Street)
    BANNOCKBURN IL 60015

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Option Care Health, Inc. [ OPCH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    GC & Corporate Secretary
    3. Date of Earliest Transaction (Month/Day/Year)
    05/19/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/19/2025 M 812 A $0 79,331 D
    Common Stock 05/19/2025 M 10,384 A $0 89,715 D
    Common Stock 05/19/2025 F 10,713 D $33.09 79,002 D
    Common Stock 2,500 I By Revocable Trust
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Unit (1) 05/19/2025 M 812 (2) (2) Common Stock 812 $0 812 D
    Restricted Stock Unit (1) 05/19/2025 M 10,384 (3) (3) Common Stock 10,384 $0 0 D
    Explanation of Responses:
    1. Each restricted stock unit represents a contingent right to receive one share of Common Stock.
    2. All restricted stock units granted in this award vest as to 25% of the underlying shares of Common Stock on each of the first, second, third and fourth anniversaries of the grant date.
    3. All restricted stock units granted in this award vested on May 19, 2025.
    /s/ Collin Smyser 05/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OPCH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPCH

    DatePrice TargetRatingAnalyst
    4/30/2025$40.00Neutral → Buy
    UBS
    1/23/2025$26.00 → $35.00Hold → Buy
    Jefferies
    1/13/2025$26.00 → $33.00Neutral → Buy
    BofA Securities
    12/5/2024$26.00Neutral
    UBS
    11/4/2024$27.00Buy → Neutral
    Goldman
    10/31/2024$38.00 → $26.00Buy → Hold
    Jefferies
    10/30/2024$43.00 → $29.00Buy → Neutral
    BofA Securities
    7/16/2024$36.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $OPCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an

    8/11/25 4:05:00 PM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

    Provides access to broad-reaching nationwide network of specialty pharmacy and ambulatory infusion suites across the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has formed a strategic relationship with Option Care Health, Inc. (NASDAQ:OPCH), the nation's largest independent provider of home and ambulatory infusion services, to support the commercial development and efficient launch of Quince's lead asset, encapsulated dexamethasone sodium phosphate (eDSP) in the U.S., assuming positive study results and subsequent regulatory approval.

    8/7/25 8:00:00 AM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Option Care Health Announces Financial Results for the Second Quarter Ended June 30, 2025

    BANNOCKBURN, Ill., July 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenue of $1,416.1 million, up 15.4% compared to $1,227.2 million in the second quarter of 2024Gross profit of $269.0 million, or 19.0% of net revenue, up 7.9% compared to $249.4 million, or 20.3% of net revenue, in the second quarter of 2024Net income of $50.5 million, compared to net income of $53.0 million, in the second quarter of 20

    7/30/25 7:00:00 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Maggio Nicole was granted 7,167 shares, increasing direct ownership by 37% to 26,476 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    8/8/25 4:23:53 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    GC & Corporate Secretary Smyser Collin covered exercise/tax liability with 10,713 shares and converted options into 11,196 shares, increasing direct ownership by 0.62% to 79,002 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    5/21/25 4:17:53 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Director Betten Elizabeth Quadros was granted 5,034 shares, increasing direct ownership by 24% to 26,373 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    5/19/25 6:28:58 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kraemer Harry M Jansen Jr bought $969,031 worth of shares (43,000 units at $22.54), increasing direct ownership by 15% to 326,334 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    11/13/24 5:27:03 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Kraemer Harry M Jansen Jr bought $1,104,352 worth of shares (35,000 units at $31.55), increasing direct ownership by 15% to 269,528 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    2/28/24 4:41:59 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Bierbower Elizabeth D bought $79,110 worth of shares (3,000 units at $26.37), increasing direct ownership by 29% to 13,515 units (SEC Form 4)

    4 - Option Care Health, Inc. (0001014739) (Issuer)

    11/1/23 5:09:51 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Option Care Health Inc.

    SCHEDULE 13G/A - Option Care Health, Inc. (0001014739) (Subject)

    8/12/25 10:34:26 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    SEC Form 10-Q filed by Option Care Health Inc.

    10-Q - Option Care Health, Inc. (0001014739) (Filer)

    7/30/25 4:01:23 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Option Care Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Option Care Health, Inc. (0001014739) (Filer)

    7/30/25 6:58:17 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Option Care Health upgraded by UBS with a new price target

    UBS upgraded Option Care Health from Neutral to Buy and set a new price target of $40.00

    4/30/25 7:24:45 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Option Care Health upgraded by Jefferies with a new price target

    Jefferies upgraded Option Care Health from Hold to Buy and set a new price target of $35.00 from $26.00 previously

    1/23/25 7:51:53 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Option Care Health upgraded by BofA Securities with a new price target

    BofA Securities upgraded Option Care Health from Neutral to Buy and set a new price target of $33.00 from $26.00 previously

    1/13/25 12:17:48 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Financials

    Live finance-specific insights

    View All

    Option Care Health Announces Financial Results for the Second Quarter Ended June 30, 2025

    BANNOCKBURN, Ill., July 30, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights Net revenue of $1,416.1 million, up 15.4% compared to $1,227.2 million in the second quarter of 2024Gross profit of $269.0 million, or 19.0% of net revenue, up 7.9% compared to $249.4 million, or 20.3% of net revenue, in the second quarter of 2024Net income of $50.5 million, compared to net income of $53.0 million, in the second quarter of 20

    7/30/25 7:00:00 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Option Care Health to Announce Second Quarter 2025 Financial Results and Host Conference Call

    BANNOCKBURN, Ill., June 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its second quarter ended June 30, 2025 on Wednesday, July 30, 2025 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day. Conference Call DetailsParticipants can pre-register for the conference call at the following link: https://register-conf.media-server.com/register/BI6761a41f2d314134ba5d574509278b8d. The call can also be accessed via a liv

    6/25/25 4:05:00 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2025

    BANNOCKBURN, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ:OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights Net revenue of $1,333.0 million, up 16.3% compared to $1,146.1 million in the first quarter of 2024Gross profit of $263.1 million, or 19.7% of net revenue, up 10.3% compared to $238.5 million, or 20.8% of net revenue, in the first quarter of 2024Net income of $46.7 million, compared to net income of $44.8 million, in the first quarter of 2024 and diluted

    4/29/25 7:00:00 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Option Care Health Inc.

    SC 13G - Option Care Health, Inc. (0001014739) (Subject)

    11/8/24 10:46:38 AM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by Option Care Health Inc. (Amendment)

    SC 13G/A - Option Care Health, Inc. (0001014739) (Subject)

    2/13/24 5:12:03 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by Option Care Health Inc. (Amendment)

    SC 13G/A - Option Care Health, Inc. (0001014739) (Subject)

    9/11/23 1:33:44 PM ET
    $OPCH
    Medical/Nursing Services
    Health Care

    $OPCH
    Leadership Updates

    Live Leadership Updates

    View All

    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an

    8/11/25 4:05:00 PM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers

    NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Barbara W. Bodem and David Keeling to its Board of Managers, effective February 12, 2024. Following these appointments, the Board will comprise of 8 directors, 5 of whom are non-executive. "We are pleased to welcome Barbara and David to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Barbara's deep experience serving in senior finance and board roles in leading edge pharmaceutical and

    2/27/24 9:00:00 AM ET
    $BMRN
    $ENOV
    $OPCH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties
    Medical/Nursing Services

    Riverbed|Aternity Announces Appointment of New Board of Directors

    New Board Brings Significant and Diverse Experience to Support Company's Growth and Success Riverbed|Aternity (the "Company") today announced that, as part of its recapitalization, which was finalized today, the following seven directors have been appointed to the Company's new Board of Directors (the "Board"). These appointments became effective on December 7, 2021, upon the completion of the Company's recapitalization and voluntary court-supervised process. "We are pleased to welcome our new directors, a group of seasoned, accomplished and respected business leaders who will bring a wide and diverse range of skills to the Riverbed|Aternity Board," said Dan Smoot, President and CEO of Ri

    12/7/21 6:32:00 PM ET
    $MODV
    $OPCH
    Transportation Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care